

Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAplus patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
 information from the epoline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAplus enhanced with printed Chemical Abstracts
 page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAplus currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
 comprehensive access to substance and sequence
 information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
 to be discontinued
NEWS 12 SEP 25 CA/CAplus current-awareness alert options enhanced
 to accommodate supplemental CAS indexing of
 exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
 and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
 display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
 prophetic substances identified in new Japanese-
 language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
 number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing
 enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
 Applications
NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
 pre-registered REACH substances
NEWS 22 NOV 21 CAS patent coverage to include exemplified prophetic
 substances identified in English-, French-, German-,
 and Japanese-language basic patents from 2004-present
NEWS 23 NOV 26 MARPAT enhanced with FSORT command
NEWS 24 NOV 26 MEDLINE year-end processing temporarily halts
 availability of new fully-indexed citations
NEWS 25 NOV 26 CHEMSAFE now available on STN Easy
NEWS 26 NOV 26 Two new SET commands increase convenience of STN
 searching
NEWS 27 DEC 01 ChemPort single article sales feature unavailable

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 18:09:12 ON 01 DEC 2008

=> file reg
COST IN U.S. DOLLARS
SINCE FILE ENTRY
SESSION
TOTAL
0.21
0.21
FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 18:09:30 ON 01 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2
DICTIONARY FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stnqgen/stndoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10586420.str



chain nodes :

6 7 17 29 30 31 32 33

ring nodes :

1 2 3 4 5 8 9 10 11 12 13 14 15 16 19 20 21 22 23 24 25 26 27
28

chain bonds :

2-6 3-8 4-19 5-7 11-17 24-29 27-30 30-31 31-32 31-33

ring bonds :

1-2 1-5 2-3 3-4 4-5 8-9 8-10 9-12 9-13 10-11 11-12 12-16 13-14 14-15
15-16 19-20 19-24 20-21 20-25 21-22 21-28 22-23 23-24 25-26 26-27 27-28

exact/norm bonds :

1-2 1-5 2-6 5-7 10-11 11-12 11-17 30-31 31-32 31-33

exact bonds :

2-3 3-4 3-8 4-5 4-19 8-9 8-10 24-29 27-30

normalized bonds :

9-12 9-13 12-16 13-14 14-15 15-16 19-20 19-24 20-21 20-25 21-22 21-28

22-23 23-24 25-26 26-27 27-28

isolated ring systems :

containing 1 : 8 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom 29:CLASS
30:CLASS 31:CLASS 32:CLASS 33:CLASS

L1 STRUCTURE UPLOADED

=> d k1

L1 HAS NO ANSWERS

'K1 ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
ENTER STRUCTURE FORMAT (SIM), NOS:end

=> d 11
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss full
FULL SEARCH INITIATED 18:10:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 239 TO ITERATE

100.0% PROCESSED 239 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

L2 1 SEA SSS FUL L1

=> file cap1
COST IN U.S. DOLLARS SINCE FILE TOTAL
FULL ESTIMATED COST ENTRY SESSION
178.82 179.03

FILE 'CAPLUS' ENTERED AT 18:10:30 ON 01 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2008 VOL 149 ISS 23
FILE LAST UPDATED: 30 Nov 2008 (20081130/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 12
L3 1 L2


=> d 13 ibib hitstr

L3 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:673287 CAPLUS
DOCUMENT NUMBER: 143:172756
TITLE: Preparation of indolylmaleimide derivatives as PKC

INVENTOR(S): inhibitors
Van Eis, Maurice; Von Matt, Peter; Wagner, Juergen;
Evenou, Jean-Pierre
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068454	A1	20050728	WO 2005-EP501	20050119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205182	A1	20050728	AU 2005-205182	20050119
CA 2552738	A1	20050728	CA 2005-2552738	20050119
EP 1709030	A1	20061011	EP 2005-701051	20050119
EP 1709030	B1	20080402		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1910174	A	20070207	CN 2005-80002734	20050119
JP 2007518730	T	20070712	JP 2006-548286	20050119
BR 2005006958	A	20070724	BR 2005-6958	20050119
AT 391127	T	20080415	AT 2005-701051	20050119
ES 2303218	T3	20080801	ES 2005-701051	20050119
MX 2006PA08159	A	20060920	MX 2006-PA8159	20060718
KR 2007020401	A	20070221	KR 2006-714418	20060718
IN 2006CN02632	A	20070608	IN 2006-CN2632	20060719
US 20080234494	A1	20080925	US 2006-586420	20060719
PRIORITY APPLN. INFO.:			GB 2004-1089	A 20040119
			GB 2004-1090	A 20040119
			WO 2005-EP501	W 20050119

OTHER SOURCE(S): CASREACT 143:172756; MARPAT 143:172756
 IT 860646-70-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indolylmaleimide derivs. as PKC inhibitors)
 RN 860646-70-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg		SINCE FILE	TOTAL
COST IN U.S. DOLLARS		ENTRY	SESSION
FULL ESTIMATED COST		5.19	184.22

FILE 'REGISTRY' ENTERED AT 18:12:13 ON 01 DEC 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2
 DICTIONARY FILE UPDATES: 30 NOV 2008 HIGHEST RN 1077629-73-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\STNEXP\Queries\10586420a.str



chain nodes :

6 7

ring nodes :

1 2 3 4 5 8 9 10 11 12 13 14 15 16 18 19 20 21 22 23 24 25 26
27

chain bonds :

2-6 3-8 4-18 5-7

ring bonds :

1-2 1-5 2-3 3-4 4-5 8-9 8-10 9-12 9-13 10-11 11-12 12-16 13-14 14-15
15-16 18-19 18-23 19-20 19-24 20-21 20-27 21-22 22-23 24-25 25-26 26-27

exact/norm bonds :

1-2 1-5 2-6 5-7 10-11 11-12

exact bonds :

2-3 3-4 3-8 4-5 4-18 8-9 8-10

normalized bonds :

9-12 9-13 12-16 13-14 14-15 15-16 18-19 18-23 19-20 19-24 20-21 20-27
21-22 22-23 24-25 25-26 26-27

isolated ring systems :

containing 1 : 8 : 18 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 18:Atom 19:Atom 20:Atom
21:Atom 22:Atom 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom

L4 STRUCTURE UPLOADED

=> d 14

L4 HAS NO ANSWERS

L4 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s 14 sss full
FULL SEARCH INITIATED 18:12:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 389 TO ITERATE

100.0% PROCESSED 389 ITERATIONS 216 ANSWERS
SEARCH TIME: 00.00.01

L5 216 SEA SSS FUL L4
```

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	362.58

```
FILE 'CAPLUS' ENTERED AT 18:12:37 ON 01 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 1 Dec 2008 VOL 149 ISS 23
FILE LAST UPDATED: 30 Nov 2008 (20081130/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.


Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s 15
L6 16 L5


=> d 16 1-16 ibib hitstr

L6 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:398759 CAPLUS
DOCUMENT NUMBER: 148:528866
TITLE: Aryl-indolyl maleimides as inhibitors of CaMKII δ . Part 1: SAR of the aryl region
AUTHOR(S): Levy, Daniel E.; Wang, Dan-Xiong; Lu, Qing; Chen, Zheng; Perumattam, John; Xu, Yong-jin; Liclican, Albert; Higaki, Jeffrey; Dong, Hanmin; Laney, Maureen; Mavunkel, Babu; Dugar, Sundeep
CORPORATE SOURCE: Scios, Inc., Fremont, CA, 94555, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(7), 2390-2394
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:528866
IT 1024583-89-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(aryl-indolyl maleimides as inhibitors of CaMKII δ)
RN 1024583-89-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1-naphthalenyl)-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

IT 1024584-17-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(aryl-indolyl maleimides as inhibitors of CaMKII δ)
RN 1024584-17-5 CAPLUS
CN Carbamic acid, N-[3-[3-[2,5-dihydro-4-(1-naphthalenyl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:54639 CAPLUS
 DOCUMENT NUMBER: 146:163003
 TITLE: Indolylmaleimide derivatives as protein kinase inhibitors and their preparation, pharmaceutical compositions and use in the prevention and treatment of T lymphocyte mediated diseases
 INVENTOR(S): Wagner, Juergen; Van Eis, Maurice; Von Matt, Peter; Evenou, Jean-Pierre; Schuler, Walter
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 68pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007006533	A2	20070118	WO 2006-EP6732	20060710
WO 2007006533	A3	20070524		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
AU 2006268908	A1	20070118	AU 2006-268908	20060710
CA 2611607	A1	20070118	CA 2006-2611607	20060710
EP 1904482	A2	20080402	EP 2006-754708	20060710
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
IN 2007DN09350	A	20080627	IN 2007-DN9350	20071204
MX 200800463	A	20080311	MX 2008-463	20080109
KR 2008023732	A	20080314	KR 2008-700790	20080110
CN 101223162	A	20080716	CN 2006-80025403	20080111
PRIORITY APPLN. INFO.:			GB 2005-14204	A 20050711

GB 2005-14205
WO 2006-EP6732

A 20050711
W 20060710


OTHER SOURCE(S): MARPAT 146:163003
IT 860468-19-5P 919992-55-5P 919992-56-6P
919992-57-7P 919992-58-8P 919992-59-9P
919992-60-2P 919992-61-3P 919992-62-4P
919992-63-5P 919992-64-6P 919992-65-7P
919992-66-8P 919992-67-9P 919992-68-0P
919992-69-1P 919992-70-4P 919992-71-5P
919992-72-6P 919992-73-7P 919992-75-9P
919992-76-0P 919992-77-1P 919992-78-2P
919992-79-3P 919992-80-6P 919992-83-9P
919992-84-0P 919992-85-1P 919992-86-2P
919992-87-3P 919992-88-4P 919992-89-5P
919992-90-8P 919992-91-9P 919992-92-0P
919992-93-1P 919992-94-2P 919992-95-3P
919992-96-4P 919992-97-5P 919992-98-6P
919992-99-7P 919993-00-3P 919993-01-4P
919993-03-6P 919993-04-7P 919993-05-8P
919993-06-9P 919993-07-0P 919993-08-1P
919993-09-2P 919993-10-5P 919993-11-6P
919993-12-7P 919993-13-8P 919993-14-9P
919993-15-0P 919993-16-1P 919993-17-2P
919993-18-3P 919993-19-4P 919993-20-7P
919993-21-8P 919993-22-9P 919993-23-0P
919993-24-1P 919993-25-2P 919993-26-3P
919993-27-4P 919993-28-5P 919993-29-6P
919993-30-9P 919993-31-0P 919993-32-1P
919993-33-2P 919993-34-3P 919993-35-4P
919993-36-5P 919993-37-6P 919993-38-7P
919993-39-8P 919993-40-1P 919993-41-2P
919993-42-3P 919993-43-4P 919993-44-5P
919993-45-6P 919993-46-7P 919993-47-8P
919993-48-9P 919993-49-0P 919993-50-3P
919993-51-4P 919993-52-5P 919993-53-6P
919993-54-7P 919993-55-8P 919993-56-9P
919993-57-0P 919993-58-1P 919993-59-2P
919993-60-5P 919993-61-6P 919993-62-7P
919993-63-8P 919993-64-9P 919993-65-0P
919993-66-1P 919993-67-2P 919993-68-3P
919993-69-4P 919993-70-7P 919993-71-8P
919993-72-9P 919993-73-0P 919993-74-1P
919993-75-2P 919993-76-3P 919993-77-4P
919993-78-5P 919993-79-6P 919993-80-9P
919994-32-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of indolylmaleimide derivs. as protein kinase inhibitors and their use in the prevention and treatment of T lymphocyte mediated diseases)

RN 860468-19-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-55-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, 2,2,2-trifluoroacetate (1:1)
(CA INDEX NAME)

CM 1

CRN 919992-54-4


CMF C26 H21 Cl F N3 O2



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 919992-56-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-57-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-58-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-59-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-60-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-fluoroethyl)amino]methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-61-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylmethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-62-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylmethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-63-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)methylamino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-64-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-65-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-66-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-67-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-68-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-methoxyethyl)amino]methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-69-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methyl-2-propen-1-ylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-70-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-propen-1-ylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-71-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylmethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-72-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(cyclopropylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-73-7 CAPLUS

CN Acetamide, 2-[[3-[4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-7-yl]oxy]-N,N-diethyl- (CA INDEX NAME)




RN 919992-75-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-76-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-77-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-methoxypropoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-78-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6,7-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-79-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-80-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-83-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-84-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(dimethylamino)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-85-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-86-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[(2-methoxyethyl)amino]methyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919992-87-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[(2-(dimethylamino)ethyl)amino]methyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-88-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2,2,2-trifluoroethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-89-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-methoxy-3-methylbutoxy)-1H-indol-3-yl]- (CA INDEX NAME)

NAME)




RN 919992-90-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-ethoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-91-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)



RN 919992-92-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[6-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-93-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919992-94-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-methoxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-95-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-96-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(dimethylamino)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-97-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-1-(2-methoxyethyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-98-6 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxy-2-methylpropoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919992-99-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxy-2-methylpropyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-00-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-(2-aminoethyl)-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-01-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[7-(2-aminoethoxy)-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-03-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-04-7 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-fluoroethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-05-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2,2,2-trifluoroethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-06-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(trifluoromethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-07-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(difluoromethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-08-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-09-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[(7-(2-methoxyethoxy)-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-10-5 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-1H-indol-3-yl]-(CA INDEX NAME)




RN 919993-11-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-12-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-13-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(2-aminoethoxy)ethyl]-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-14-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-15-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-16-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[7-(3-aminopropoxy)-1H-indol-3-yl]-4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]- (CA INDEX NAME)




RN 919993-17-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxy-2-methylpropoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-18-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]-1H-pyrrole-2,5-dione (CA INDEX NAME)




RN 919993-19-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1H-pyrrole-2,5-dione (CA INDEX NAME)





RN 919993-20-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-1-[2-(2-methoxyethoxy)ethyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione (CA INDEX NAME)



RN 919993-21-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(2-hydroxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-22-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(3-quinoliny)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-23-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[(2-methoxyethoxy)methyl]-1H-indol-3-yl]- (CA INDEX NAME)

MeO—CH₂—CH₂—O—CH₂—CH₂—O—CH₂




RN 919993-24-1 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[(2-methoxyethoxy)methyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-25-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]-
 (CA INDEX NAME)




RN 919993-26-3 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(2-methoxyethoxy)ethyl]-7-methyl-1H-indol-3-yl]-
 (CA INDEX NAME)




RN 919993-27-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[1-[2-(2-methoxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-28-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-methoxyethyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-29-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-30-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-31-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-methoxyethoxy)ethoxy]-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-32-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-methoxyethoxy)-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-33-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-chloro-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-34-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-chloro-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-35-4 CAPLUS

CN 1H-Indole-7-carboxylic acid, 3-[4-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-2,5-dihydro-2,5-dioxo-1H-pyrrol-3-yl]-, methyl ester (CA INDEX NAME)




RN 919993-36-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(2-hydroxyethoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-37-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(3-hydroxypropoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-38-7 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-39-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxy-2-methylpropoxy)-1H-indol-3-yl]- (CA INDEX NAME)

NAME)




RN 919993-40-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-(pentyloxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-41-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-chloro-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-42-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-43-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-44-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5,7-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-45-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5,6-dimethoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-46-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(4-methyl-1-piperazinyl)ethoxy]-1H-indol-3-yl] - (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 919993-47-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(2-hydroxyethoxy)ethoxy]-1-methyl-1H-indol-3-yl] - (CA INDEX NAME)



RN 919993-48-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(methylamino)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-49-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-[2-(1H-imidazol-2-yl)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-50-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-[2-(1H-imidazol-2-yl)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-51-4 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-methoxy-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-52-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-hydroxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-53-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-hydroxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-54-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-(2-methoxyethoxy)-5,7-dimethyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-55-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxyethoxy)ethoxy]-5,7-dimethyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-56-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-6-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-57-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[7-methoxy-6-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-58-1 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-fluoro-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-59-2 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-fluoro-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-60-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-fluoro-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-61-6 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxy-2-methylpropoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-62-7 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-methoxy-2-methylpropoxy)ethoxy]-1-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-63-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[6-[2-(2-hydroxy-2-methylpropoxy)ethoxy]-1-methyl-1H-indol-

3-y1] - (CA INDEX NAME)




RN 919993-64-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-[2-(2-methoxyethoxy)ethoxy]-1-[2-(2-methoxyethoxy)ethyl]-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-65-0 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-chloro-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-66-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-(2-methoxyethoxy)-1-(2-methoxyethyl)-1H-indol-


3-y1]- (CA INDEX NAME)



RN 919993-67-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-68-3 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-chloro-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-69-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[6-(2-methoxy-2-methylpropoxy)-1-methyl-1H-indol-3-yl]-
(CA INDEX NAME)




RN 919993-70-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-71-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(3-hydroxypropyl)-1H-indol-3-yl]- (CA INDEX NAME)



RN 919993-72-9 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-

naphthalenyl]-4-[1-(3-hydroxypropyl)-7-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-73-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-7-methoxy-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-74-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-ethyl-7-[2-(2-methoxyethoxy)ethoxy]-1H-indol-3-yl]-(CA INDEX NAME)




RN 919993-75-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[5-ethyl-7-(2-methoxyethoxy)-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-76-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-ethyl-7-methoxy-1H-indol-3-yl)- (CA INDEX NAME)




RN 919993-77-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-5-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-78-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-[1-(2-hydroxyethyl)-6-methyl-1H-indol-3-yl]- (CA INDEX NAME)




RN 919993-79-6 CAPLUS

CN Acetamide, N-[[7-chloro-8-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]methyl]-N-methyl- (CA INDEX NAME)




RN 919993-80-9 CAPLUS

CN Acetamide, N-[[7-chloro-8-[2,5-dihydro-4-(1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]methyl]-N-methyl- (CA INDEX NAME)



RN 919994-32-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(2-(dimethylamino)ethyl)methylamino]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




IT 919994-33-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of indolylmaleimide derivs. as protein kinase inhibitors and their use in the prevention and treatment of T lymphocyte mediated diseases)

RN 919994-33-5 CAPLUS

CN Carbamic acid, N-[(7-chloro-8-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl)methyl]-N-(2-fluoroethyl)-, 1,1-dimethylethyl ester (CA INDEX NAME)



L6 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:984206 CAPLUS

DOCUMENT NUMBER: 145:505290

TITLE: A practical method for the synthesis of indolylaryl- and bisindolylmaleimides

AUTHOR(S): Roy, Sudipta; Roy, Sujata; Gribble, Gordon W.

CORPORATE SOURCE: Department of Chemistry, Dartmouth College, Hanover, NH, 03755, USA

SOURCE: Organic Letters (2006), 8(21), 4975-4977

CODEN: ORLEF7; ISSN: 1523-7060

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:505290


IT 125313-42-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of indolyl(aryl)maleimides via acylation of N-methylindole with oxalyl chloride followed by amidation and cyclocondensation with arylacetates)

RN 125313-42-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:94622 CAPLUS

DOCUMENT NUMBER: 144:350471

TITLE: Design, Synthesis, and Biological Evaluation of 3,4-Diarylmaleimides as Angiogenesis Inhibitors
Peifer, Christian; Stoiber, Thomas; Unger, Eberhard; Totzke, Frank; Schaechtele, Christoph; Marne, Dieter; Brenk, Ruth; Klebe, Gerhard; Schollmeyer, Dieter; Dannhardt, Gerd

CORPORATE SOURCE: Department of Pharmacy, Johannes Gutenberg-University, Mainz, D-55099, Germany

SOURCE: Journal of Medicinal Chemistry (2006), 49(4), 1271-1281

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


OTHER SOURCE(S): CASREACT 144:350471

IT 221233-51-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of diarylmaleimides by cyclocondensation of arylglyoxylates with arylacetamides as angiogenesis inhibitors)

RN 221233-51-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:673288 CAPLUS
DOCUMENT NUMBER: 143:153287
TITLE: Preparation of indolylmaleimide derivatives as PKC inhibitors
INVENTOR(S): Van Eis, Maurice; Von Matt, Peter; Wagner, Juergen; Evenou, Jean-Pierre; Schuler, Walter
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068455	A1	20050728	WO 2005-EP502	20050119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005205183	A1	20050728	AU 2005-205183	20050119
CA 2552740	A1	20050728	CA 2005-2552740	20050119
EP 1745037	A1	20070124	EP 2005-701052	20050119
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1910173	A	20070207	CN 2005-80002684	20050119
BR 2005006939	A	20070612	BR 2005-6939	20050119
JP 2007518731	T	20070712	JP 2006-548287	20050119
AT 391127	T	20080415	AT 2005-701051	20050119
ES 2303218	T3	20080801	ES 2005-701051	20050119
MX 2006PA08158	A	20070130	MX 2006-PA8158	20060718
KR 2007021123	A	20070222	KR 2006-714416	20060718
IN 2006CN02629	A	20070608	IN 2006-CN2629	20060719
US 20080242675	A1	20081002	US 2006-586421	20061018
PRIORITY APPLN. INFO.:			GB 2004-1089	A 20040119
			GB 2004-1090	A 20040119
			WO 2005-EP502	W 20050119

OTHER SOURCE(S): CASREACT 143:153287; MARPAT 143:153287

IT 860468-10-6P 860468-11-7P 860468-12-8P
860468-13-9P 860468-14-0P 860468-15-1P
860468-16-2P 860468-17-3P 860468-18-4P
860468-19-5P 860468-20-8P 860468-21-9P
860468-22-0P 860468-23-1P 860468-24-2P
860468-25-3P 860468-26-4P 860468-27-5P
860468-28-6P 860468-29-7P 860468-30-0P
860468-31-1P 860468-32-2P 860468-33-3P
860468-34-4P 860468-35-5P 860468-36-6P
860468-37-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolylmaleimide derivs. as PKC inhibitors)

RN 860468-10-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-11-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, acetate (1:2) (CA INDEX NAME)

CM 1

CRN 860468-10-6


CMF C26 H22 Cl N3 O2



CM 2

CRN 64-19-7


CMF C2 H4 O2



RN 860468-12-8 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-chloro-1-naphthalenyl]-4-(1-

methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-13-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-14-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-15-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-16-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-17-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(methylamino)methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-18-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-19-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-20-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(6-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-21-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(dimethylamino)methyl]-1-naphthalenyl]-4-(5-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-22-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(ethylmethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-23-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(diethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-24-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(ethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-25-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(1-methylethyl)amino]methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-26-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-[(4-methyl-1-piperazinyl)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-27-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-7-(1-pyrrolidinylmethyl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-28-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1,7-dimethyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-29-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-30-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-31-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-2-methyl-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-32-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-33-3 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-[7-(aminomethyl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-34-4 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(7-amino-1-naphthalenyl)-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-35-5 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(7-amino-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860468-36-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[7-[(dimethylamino)methyl]-2-fluoro-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860468-37-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[7-[(dimethylamino)methyl]-2-fluoro-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:673287 CAPLUS

DOCUMENT NUMBER: 143:172756

TITLE: Preparation of indolylmaleimide derivatives as PKC inhibitors

INVENTOR(S): Van Eis, Maurice; Von Matt, Peter; Wagner, Juergen; Evenou, Jean-Pierre

PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005068454	A1	20050728	WO 2005-EP501	20050119
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG
 AU 2005205182 A1 20050728 AU 2005-205182 20050119
 CA 2552738 A1 20050728 CA 2005-2552738 20050119
 EP 1709030 A1 20061011 EP 2005-701051 20050119
 EP 1709030 B1 20080402
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
 CN 1910174 A 20070207 CN 2005-80002734 20050119
 JP 2007518730 T 20070712 JP 2006-548286 20050119
 BR 2005006958 A 20070724 BR 2005-6958 20050119
 AT 391127 T 20080415 AT 2005-701051 20050119
 ES 2303218 T3 20080801 ES 2005-701051 20050119
 MX 2006PA08159 A 20060920 MX 2006-PA8159 20060718
 KR 2007020401 A 20070221 KR 2006-714418 20060718
 IN 2006CN02632 A 20070608 IN 2006-CN2632 20060719
 US 20080234494 A1 20080925 US 2006-586420 20060719
 PRIORITY APPLN. INFO.: GB 2004-1089 A 20040119
 GB 2004-1090 A 20040119
 WO 2005-EP501 W 20050119

OTHER SOURCE(S): CASREACT 143:172756; MARPAT 143:172756


IT 860646-70-4P 860646-71-5P 860646-72-6P
 860646-73-7P 860646-74-8P 860646-75-9P
 860646-76-0P 860646-77-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolylmaleimide derivs. as PKC inhibitors)


RN 860646-70-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-71-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-72-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-73-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-74-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(dimethylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-75-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(methylamino)methyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 860646-76-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[2-chloro-6-[(methylamino)methyl]-1-naphthalenyl]-4-(7-methyl-1H-indol-3-yl)- (CA INDEX NAME)



RN 860646-77-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[6-(aminomethyl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:991343 CAPLUS
 DOCUMENT NUMBER: 140:42028
 TITLE: Preparation of substituted 1H-pyrrole-2,5-diones as kinase inhibitors
 INVENTOR(S): Zhang, Han-cheng; Maryanoff, Bruce E.; Mccomsey, David F.; White, Kimberly; Ye, Hong; Hecker, Leonard; Conway, Bruce R.; Demarest, Keith
 PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
 SOURCE: PCT Int. Appl., 101 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003103663	A2	20031218	WO 2003-US17518	20030604
WO 2003103663	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2488798	A1	20031218	CA 2003-2488798	20030604
AU 2003240517	A1	20031222	AU 2003-240517	20030604
US 20040054180	A1	20040318	US 2003-454561	20030604
US 7232906	B2	20070619		
EP 1513520	A2	20050316	EP 2003-731528	20030604
EP 1513520	B1	20080924		
R: AT, BE, CH, DE, DK, ES, FR, IE, SI, LT, LV, FI, RO, MK,	GB, GR, IT, LI, LU, NL, SE, MC, PT, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005531607	T	20051020	JP 2004-510782	20030604
AT 409035	T	20081015	AT 2003-731528	20030604
US 20070213386	A1	20070913	US 2007-800878	20070508
US 20070213387	A1	20070913	US 2007-800912	20070508
PRIORITY APPLN. INFO.:			US 2002-386002P	P 20020605
			US 2003-454561	A3 20030604
			WO 2003-US17518	W 20030604

OTHER SOURCE(S): MARPAT 140:42028


IT 634605-00-8P 634605-01-9P 634605-02-0P
 634605-03-1P 634605-04-2P 634605-05-3P
 634605-34-8P 634605-36-0P 634605-41-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of substituted 1H-pyrrole-2,5-diones as kinase inhibitors)
 RN 634605-00-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-ethenyl-1H-indol-3-yl)-4-(2-hydroxy-1-naphthalenyl)- (CA INDEX NAME)



RN 634605-01-9 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[2-[3-(dimethylamino)-2-hydroxypropoxy]-1-naphthalenyl]-4-(1-ethenyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 634605-02-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-hydroxy-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 634605-03-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(2-butyn-1-ylmethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 634605-04-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(3-butyn-1-ylmethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 634605-05-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-naphthalenyl)-4-[1-(5-pyrimidinyl)-1H-indol-3-yl]- (CA INDEX NAME)




RN 634605-34-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)




RN 634605-36-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[1-[2-(diethylamino)ethyl]-1H-indol-3-yl]-4-(1-naphthalenyl)- (CA INDEX NAME)



RN 634605-41-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-naphthalenyl)-4-[1-(5-pyrimidinyl)-1H-indol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

L6 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:796695 CAPLUS
 DOCUMENT NUMBER: 139:307678
 TITLE: Preparation of indolylmaleimides for treating diseases or disorders mediated by T lymphocytes and/or PKC
 INVENTOR(S): Evenou, Jean-Pierre; Von Matt, Peter; Wagner, Juergen; Zenke, Gerhard
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 33 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003082859	A1	20031009	WO 2003-EP3470	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
CA 2477774	A1	20031009	CA 2003-2477774	20030402
AU 2003224031	A1	20031013	AU 2003-224031	20030402
AU 2003224031	B2	20070628		
EP 1490355	A1	20041229	EP 2003-720413	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003008979	A	20050104	BR 2003-8979	20030402
CN 1639153	A	20050713	CN 2003-805343	20030402
CN 100351251	C	20071128		
JP 2005527563	T	20050915	JP 2003-580325	20030402
NZ 535613	A	20070727	NZ 2003-535613	20030402
IN 2004CN02172	A	20060303	IN 2004-CN2172	20040929
MX 2004PA09632	A	20050111	MX 2004-PA9632	20041001
US 20050119274	A1	20050602	US 2004-510027	20041001

NO 2004004613	A 20041026	NO 2004-4613	20041026
ZA 2004006545	A 20060531	ZA 2004-6545	20060327
US 20070032507	A1 20070208	US 2006-546690	20061012
US 7358253	B2 20080415		
US 20070037826	A1 20070215	US 2006-546693	20061012
US 7235555	B2 20070626		
KR 2007043900	A 20070425	KR 2007-707917	20070406
US 20080108628	A1 20080508	US 2007-977565	20071025
US 20080146578	A1 20080619	US 2008-34675	20080221
PRIORITY APPLN. INFO.:			
		GB 2002-7729	A 20020403
		GB 2003-3323	A 20030213
		WO 2003-EP3470	W 20030402
		KR 2004-715591	A3 20041001
		US 2004-510027	A1 20041001
		US 2006-546690	A1 20061012

OTHER SOURCE(S): MARPAT 139:307678


IT 611234-31-2P 611234-32-3P 611234-33-4P
 611234-34-5P 611234-35-6P 611234-36-7P
 611234-37-8P 611234-38-9P 611234-40-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolylmaleimides for treating diseases or disorders mediated by T lymphocytes and/or PKC)

RN 611234-31-2 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 611234-32-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 611234-31-2
 CMF C29 H26 N4 O2




CM 2

CRN 76-05-1
 CMF C2 H F3 O2




RN 611234-33-4 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[(3R)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 611234-34-5 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-[3-(4,7-diazaspiro[2.5]oct-7-yl)-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 611234-35-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[(3R)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-36-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-[(3S)-3-methyl-1-piperazinyl]-1-naphthalenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-37-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[(3S)-3-methyl-1-piperazinyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-38-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[(3S)-3,4-dimethyl-1-piperazinyl]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 611234-40-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[(3S)-3,4-dimethyl-1-piperazinyl]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN


ACCESSION NUMBER: 2003:795114 CAPLUS

DOCUMENT NUMBER: 140:42054

TITLE: Aryl[a]pyrrolo[3,4-c]carbazoles as selective cyclin D1-CDK4 inhibitors


AUTHOR(S): Sanchez-Martinez, Concha; Shih, Chuan; Faul, Margaret M.; Zhu, Guoxin; Paal, Michael; Somoza, Carmen; Li, Tiechao; Kumrich, Christine A.; Winneroski, Leonard L.; Xun, Zhou; Brooks, Harold B.; Patel, Bharvin K. R.; Schultz, Richard M.; DeHahn, Tammy B.; Spencer,

CORPORATE SOURCE: Charles D.; Watkins, Scott A.; Considine, Eileen;
 SOURCE: Dempsey, Jack A.; Ogg, Catherine A.; Campbell, Robert
 M.; Anderson, Bryan A.; Wagner, Jill
 DCR&T, Lilly Spain S.A., Madrid, 28108, Spain
 Bioorganic & Medicinal Chemistry Letters (2003),
 13(21), 3835-3839
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Science B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 140:42054
 IT 221233-51-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of maleimides via heterocyclization of indolylglyoxylate with
 arylacetamides followed by elimination in the preparation of
 arenopyrrolocarbazoles as cyclin D1-CDK4 inhibitors)
 RN 221233-51-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX
 NAME)




REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:743245 CAPLUS
 DOCUMENT NUMBER: 139:307698
 TITLE: Synthesis of Aryl- and
 Heteroaryl[a]pyrrolo[3,4-c]carbazoles
 AUTHOR(S): Sanchez-Martinez, Concha; Faul, Margaret M.; Shih,
 Chuan; Sullivan, Kevin A.; Grutsch, John L.; Cooper,
 Jeremy T.; Kolis, Stanley P.
 CORPORATE SOURCE: Lilly S.A., Alcobendas, 28108, Spain
 SOURCE: Journal of Organic Chemistry (2003), 68(21), 8008-8014
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:307698
 IT 221233-51-8P 610312-82-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of aryl- and hetero[a]pyrrolo[3,4-c]carbazoles by photochem.
 oxidation and Heck cyclization)
 RN 221233-51-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX
 NAME)



RN 610312-82-8 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(2-bromo-1-naphthyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:368469 CAPLUS
 DOCUMENT NUMBER: 136:386017
 TITLE: Preparation of indolylmaleimide derivatives as protein kinase c inhibitors
 INVENTOR(S): Albert, Rainer; Cooke, Nigel Graham; Cottens, Sylvain; Ehrhardt, Claus; Evenou, Jean-Pierre; Sedrani, Richard; Von Matt, Peter; Wagner, Juergen; Zenke, Gerhard
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
 SOURCE: PCT Int. Appl., 50 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038561	A1	20020516	WO 2001-EP12785	20011105
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				


CA 2428133	A1	20020516	CA 2001-2428133	20011105
AU 2002021810	A	20020521	AU 2002-21810	20011105
US 20030069424	A1	20030410	US 2001-7368	20011105
US 6645970	B2	20031111		
EP 1337527	A1	20030827	EP 2001-993604	20011105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015193	A	20040203	BR 2001-15193	20011105
JP 2004513168	T	20040430	JP 2002-541095	20011105
NZ 525656	A	20041224	NZ 2001-525656	20011105
AU 2002221810	B2	20050623	AU 2002-221810	20011105
NZ 535616	A	20060331	NZ 2001-535616	20011105
CN 1253449	C	20060426	CN 2001-819992	20011105
RU 2329263	C2	20080720	RU 2003-115429	20011105
HU 2003001651	A2	20081028	HU 2003-1651	20011105
TW 290553	B	20071201	TW 2001-90127656	20011107
KR 748386	B1	20070810	KR 2003-705805	20030425
ZA 2003003426	A	20040422	ZA 2003-3426	20030505
IN 2003CN00663	A	20050415	IN 2003-CN663	20030505
NO 2003002034	A	20030704	NO 2003-2034	20030506
MX 2003PA04037	A	20030819	MX 2003-PA4037	20030507
US 20040053949	A1	20040318	US 2003-660442	20030911
US 7220774	B2	20070522		
AU 2005202387	A1	20050623	AU 2005-202387	20050601
US 20070155817	A1	20070705	US 2007-708840	20070220
US 20070184061	A1	20070809	US 2007-708841	20070220
US 20070191401	A1	20070816	US 2007-708843	20070220
NO 2007001232	A	20030704	NO 2007-1232	20070306
IN 2007CN02652	A	20071012	IN 2007-CN2652	20070619
KR 2008014934	A	20080214	KR 2008-702849	20080201
PRIORITY APPLN. INFO.:				
		US 2000-246400P	P 20001107	
		US 2001-283705P	P 20010413	
		AU 2002-21810	A3 20011105	
		NZ 2001-525656	A1 20011105	
		US 2001-7368	A1 20011105	
		WO 2001-EP12785	W 20011105	
		IN 2003-CN663	A3 20030505	
		US 2003-660442	A3 20030911	
		KR 2006-717472	A3 20060829	

OTHER SOURCE(S):	MARPAT 136:386017
IT 425636-80-2P	425636-81-3P 425636-82-4P
425636-83-5P	425636-84-6P 425636-85-7P
425636-86-8P	425636-87-9P 425636-88-0P
425636-89-1P	425636-90-4P 425636-91-5P
425636-92-6P	425636-93-7P 425636-94-8P
425636-95-9P	425636-96-0P 425636-97-1P
425636-98-2P	425637-00-9P 425637-02-1P
425637-04-3P	425637-06-5P 425637-08-7P
425637-10-1P	
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)	
(drug; preparation of indolylmaleimide derivs. as protein kinase c inhibitors)	
RN 425636-80-2	CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(dimethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)	




RN 425636-81-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(1-pyrrolidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-82-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-[(2-hydroxyethyl)methylamino]ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-83-5 CAPLUS


CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(3-methoxy-1-naphthalenyl)- (CA INDEX NAME)




RN 425636-84-6 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(3-hydroxy-1-naphthalenyl)-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 425636-85-7 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[3-(dimethylamino)propoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-86-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylmethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-87-9 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylmethylamino)ethoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-88-0 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclopropylamino)ethoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-89-1 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[1-(methylamino)cyclopropyl]methoxy]-1-naphthalenyl- (CA INDEX NAME)




RN 425636-90-4 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-[(1-methylamino)cyclopropyl]methoxy]-1-naphthalenyl]-4-(1-methyl-1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-91-5 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-(4-methyl-1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-92-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-(4-methyl-1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-93-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-(1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-94-8 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-[3-(1-piperazinyl)-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-95-9 CAPLUS


CN 1-Piperazinecarboxaldehyde, 4-[4-[2,5-dihydro-4-(1-methyl-1H-indol-3-yl)-2,5-dioxo-1H-pyrrol-3-yl]-2-naphthalenyl]- (CA INDEX NAME)




RN 425636-96-0 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(1-piperidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425636-97-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(butylmethylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425636-98-2 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(cyclohexylamino)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425637-00-9 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(4-methyl-1-piperidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 425637-02-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-(2-methyl-1-pyrrolidinyl)ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425637-04-3 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(4-hydroxy-1-piperidinyl)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




RN 425637-06-5 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 425637-08-7 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-[1,4'-bipiperidin]-1'-ylethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)



RN 425637-10-1 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-[3-[2-(3-hydroxy-1-piperidinyl)ethoxy]-1-naphthalenyl]-4-(1H-indol-3-yl)- (CA INDEX NAME)




IT 425638-69-3P 425638-70-6P 425638-71-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of indolylmaleimide derivs. as protein kinase c inhibitors)


RN 425638-69-3 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-[
[(methylsulfonyl)oxy]ethoxy]-1-naphthalenyl]- (CA INDEX NAME)




RN 425638-70-6 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-[3-[2-[[tris(1-
methylethyl)silyl]oxy]ethoxy]-1-naphthalenyl]- (CA INDEX NAME)



RN 425638-71-7 CAPLUS

CN 1H-Pyrrole-2,5-dione, 3-[3-(2-hydroxyethoxy)-1-naphthalenyl]-4-(1H-indol-3-
yl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:292783 CAPLUS

DOCUMENT NUMBER: 135:122654


TITLE: Phenyliodine(III) bis(trifluoroacetate)-mediated

AUTHOR(S): Faul, M. M.; Sullivan, K. A.
 CORPORATE SOURCE: Chemical Process Research and Development Division,
 Lilly Research Laboratories, A Division of Eli Lilly
 and Company, Indianapolis, IN, 46285, USA
 SOURCE: Tetrahedron Letters (2001), 42(19), 3271-3273
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 135:122654
 IT 125313-42-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (failed PIFA-mediated oxidation)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
 INDEX NAME)




REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:83376 CAPLUS
 DOCUMENT NUMBER: 130:237430
 TITLE: A new one step synthesis of maleimides by condensation of glyoxylate esters with acetamides
 AUTHOR(S): Faul, Margaret M.; Winneroski, Leonard L.; Krumrich, Christine A.
 CORPORATE SOURCE: Chemical Process Research and Development Division, Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA
 SOURCE: Tetrahedron Letters (1999), 40(6), 1109-1112
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 130:237430
 IT 125313-42-0P 221233-51-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of maleimides by condensation of glyoxylate esters with acetamides)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
 INDEX NAME)




RN 221233-51-8 CAPLUS
CN 1H-Pyrrole-2,5-dione, 3-(1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)




REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:338467 CAPLUS
DOCUMENT NUMBER: 122:150861
ORIGINAL REFERENCE NO.: 122:27649a, 27652a
TITLE: 2-Aryl-indolyl maleimides - novel and potent inhibitors of protein kinase C
AUTHOR(S): Hendricks, Robert T.; Sherman, D.; Strulovici, Berta; Broka, Chris A.
CORPORATE SOURCE: Inst. Org. Chem., Syntex Discovery Res., Palo Alto, CA, 94304, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(1), 67-72
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 161404-52-0
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(preparation of arylindolyl maleimides as novel and potent inhibitors of protein kinase C in relation to antitumor activity)
RN 161404-52-0 CAPLUS
CN Carbamimidothioic acid, 3-[3-[2,5-dihydro-4-(1-naphthalenyl)-2,5-dioxo-1H-pyrrol-3-yl]-1H-indol-1-yl]propyl ester, monohydrobromide (9CI) (CA INDEX NAME)



● HBr


L6 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1992:41230 CAPLUS
 DOCUMENT NUMBER: 116:41230
 ORIGINAL REFERENCE NO.: 116:7065a,7068a
 TITLE: Inhibitors of protein kinase C. 1.
 2,3-bisarylmaleimides
 AUTHOR(S): Davis, Peter D.; Hill, Christopher H.; Lawton,
 Geoffrey; Nixon, John S.; Wilkinson, Sandra E.; Hurst,
 Steven A.; Keech, Elizabeth; Turner, Susan E.
 CORPORATE SOURCE: Roche Prod. Ltd., Welwyn Garden City/Herts., AL7 3AY,
 UK
 SOURCE: Journal of Medicinal Chemistry (1992), 35(1), 177-84
 CODEN: JMCMAR; ISSN: 0022-2623
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 116:41230
 IT 125313-42-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation and protein kinase C inhibiting activity of)
 RN 125313-42-0 CAPLUS
 CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA
 INDEX NAME)



L6 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:98378 CAPLUS
 DOCUMENT NUMBER: 112:98378

ORIGINAL REFERENCE NO.: 112:16731a,16734a
 TITLE: Preparation of 3-(3-indolyl)pyrrole-2,5-diones and
 analogs as protein kinase inhibitors
 INVENTOR(S): Davis, Peter David; Hill, Christopher Huw; Lawton,
 Geoffrey
 PATENT ASSIGNEE(S): Hoffmann-La Roche, F., und Co. A.-G., Switz.
 SOURCE: Eur. Pat. Appl., 38 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 328026	A1	19890816	EP 1989-102025	19890206
EP 328026	B1	19930428		
R: AT, BE, CH, ZA 8900865	DE, ES, FR, GB, GR, IT, LI, LU, NL, SE A	19891025	ZA 1989-865	19890203
CZ 280738	B6	19960417	CZ 1989-752	19890203
SK 278989	B6	19980506	SK 1989-752	19890203
AU 8929658	A	19890810	AU 1989-29658	19890206
AU 623630	B2	19920521		
HU 49348	A2	19890928	HU 1989-554	19890206
HU 201054	B	19900928		
US 5057614	A	19911015	US 1989-307104	19890206
AT 88704	T	19930515	AT 1989-102025	19890206
CA 1320194	C	19930713	CA 1989-590178	19890206
ES 2054890	T3	19940816	ES 1989-102025	19890206
DK 8900558	A	19890811	DK 1989-558	19890207
DK 171891	B1	19970804		
JP 01233281	A	19890919	JP 1989-27741	19890208
JP 07030071	B	19950405		
NO 8900568	A	19890811	NO 1989-568	19890209
NO 172540	B	19930426		
NO 172540	C	19930804		
SU 1799382	A3	19930228	SU 1989-4613492	19890209
FI 8900652	A	19890811	FI 1989-652	19890210
FI 96861	B	19960531		
FI 96861	C	19960910		
US 36736	E	20000613	US 1998-14198	19980127
PRIORITY APPLN. INFO.:			GB 1988-3048	A 19880210
			GB 1988-27565	A 19881125
			EP 1989-102025	A 19890206
			US 1989-307104	A5 19890206
IT 125313-42-0P				
RL: SPN (Synthetic preparation); PREP (Preparation)				
(preparation of, as protein kinase inhibitor)				
RN 125313-42-0 CAPLUS				
CN 1H-Pyrrole-2,5-dione, 3-(1-methyl-1H-indol-3-yl)-4-(1-naphthalenyl)- (CA INDEX NAME)				



=>